Asset profile
BI 3006337
Unknown / undisclosed
Evidence outlook · lead readout
NCT05970640 · Non-alcoholic Fatty Liver Disease, Obesity
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05970640: This was a real randomized, placebo-controlled, single-blind trial, but its primary endpoint measured drug-related side effects rather than a clinical or disease-defining outcome, so it is evidence of tolerability at these doses rather than of clinical benefit.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.